Apr 30, 2024, 1:18 PM
Apr 30, 2024, 1:04 PM
Eli lilly sees profit boost with new drugs despite supply issues
- Eli Lilly reported better-than-expected first-quarter profit despite supply issues.
- Sales of obesity drug Zepbound and diabetes drug Mounjaro drove the profit increase.
- Demand for the drugs outpaced production hikes, leading to supply issues.
Opinions
You've reached the end